hydroxyethyl 1 piperazineethanesulfonic acid hepes (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
96
Structured Review
Thermo Fisher
hydroxyethyl 1 piperazineethanesulfonic acid hepes
Hydroxyethyl 1 Piperazineethanesulfonic Acid Hepes, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+buffer/HEPES%2C+0%2E5M+buffer+soln%2E%2C+pH+7%2E5/pm42097025-210-30-39
Average 96 stars, based on 1 article reviews
Hydroxyethyl 1 Piperazineethanesulfonic Acid Hepes, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+buffer/HEPES%2C+0%2E5M+buffer+soln%2E%2C+pH+7%2E5/pm42097025-210-30-39
Average 96 stars, based on 1 article reviews
hydroxyethyl 1 piperazineethanesulfonic acid hepes - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
other:Article Title: Neonatal expression of human FMRP isoform corrects cortical deficits and improves behavior in a mouse model of fragile X syndrome Article Snippet: The following antibodies were used: goat anti-mouse Alexa 488 (#4408, 1:500; Cell Signaling Technology, MA, USA) and Knock-Out:Article Title: A molecularly defined polymeric platform for environmentally responsive activation of STING to enhance cancer immunotherapy. Article Snippet: The stimulator of interferon genes (STING) pathway is a promising immuno-oncology target.. Despite their potential, STING agonists have yielded underwhelming results in clinical trials due to pharmacological barriers that limit their safety and efficacy.. Herein, we describe the design and pre-clinical evaluation of a polymeric dimeric amidobenzimidazole (diABZI) STING agonist delivery platform for cancer immunotherapy. Cell Culture:Article Title: A molecularly defined polymeric platform for environmentally responsive activation of STING to enhance cancer immunotherapy. Article Snippet: The stimulator of interferon genes (STING) pathway is a promising immuno-oncology target.. Despite their potential, STING agonists have yielded underwhelming results in clinical trials due to pharmacological barriers that limit their safety and efficacy.. Herein, we describe the design and pre-clinical evaluation of a polymeric dimeric amidobenzimidazole (diABZI) STING agonist delivery platform for cancer immunotherapy. Article Title: Lyophilized bacteria-infected tumor cells for targeted immunotherapy of lung metastases and associated fibrosis Article Snippet: .. 4T1 cells were cultured in DMEM with 10% FBS, 1% penicillin/streptomycin (Gibco), 2% sodium bicarbonate (Gibco), 1% 1 M Yeast:Article Title: MtvS1 and MtvS2 Interact with RNA polymerase to regulate the Francisella type V-A CRISPR-Cas system. Article Snippet: First, the cells were cooled on ice for 30min before washed twice with cold 10%glycerol (Sigma-Aldrich). .. Thewashed cellswere resuspended in cold Polymerase Chain Reaction:Article Title: MtvS1 and MtvS2 Interact with RNA polymerase to regulate the Francisella type V-A CRISPR-Cas system. Article Snippet: First, the cells were cooled on ice for 30min before washed twice with cold 10%glycerol (Sigma-Aldrich). .. Thewashed cellswere resuspended in cold Sequencing:Article Title: MtvS1 and MtvS2 Interact with RNA polymerase to regulate the Francisella type V-A CRISPR-Cas system. Article Snippet: First, the cells were cooled on ice for 30min before washed twice with cold 10%glycerol (Sigma-Aldrich). .. Thewashed cellswere resuspended in cold Transwells:Article Title: Gasdermin D-mediated delivery of caspase inhibitors to suppress pyroptosis. Article Snippet: Caspase-1, -4, -5 and -11 activate gasdermin D (GSDMD) pores, causing pyroptotic cell death and the release of the interleukins IL-1β and IL-18 (ref. 1).. Blocking this pathway holds therapeutic promise for the treatment of inflammatory disorders, but cellpermeable caspase inhibitors have not proved successful in clinical trials.. Here we describe covalent caspase inhibitors that selectively block pyroptosis and IL-1β secretion despite being excluded from healthy cells. Sterility:Article Title: Gasdermin D-mediated delivery of caspase inhibitors to suppress pyroptosis. Article Snippet: Caspase-1, -4, -5 and -11 activate gasdermin D (GSDMD) pores, causing pyroptotic cell death and the release of the interleukins IL-1β and IL-18 (ref. 1).. Blocking this pathway holds therapeutic promise for the treatment of inflammatory disorders, but cellpermeable caspase inhibitors have not proved successful in clinical trials.. Here we describe covalent caspase inhibitors that selectively block pyroptosis and IL-1β secretion despite being excluded from healthy cells. Staining:Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate Article Snippet: .. P‐gp staining was performed by fixing spheroids with 4% PFA for 15 min at 25°C, followed by permeabilization with 0.5% (v/v) Tween‐20 for 10 min. After blocking with 2% Spheroids:Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate Article Snippet: .. P‐gp staining was performed by fixing spheroids with 4% PFA for 15 min at 25°C, followed by permeabilization with 0.5% (v/v) Tween‐20 for 10 min. After blocking with 2% Blocking Assay:Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate Article Snippet: .. P‐gp staining was performed by fixing spheroids with 4% PFA for 15 min at 25°C, followed by permeabilization with 0.5% (v/v) Tween‐20 for 10 min. After blocking with 2% Incubation:Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate Article Snippet: .. P‐gp staining was performed by fixing spheroids with 4% PFA for 15 min at 25°C, followed by permeabilization with 0.5% (v/v) Tween‐20 for 10 min. After blocking with 2% |